Sökning: WFRF:(Öberg Kjell 1946 )
> (2017)
> Ramage John >
Understanding the P...
Understanding the Patient Experience with Carcinoid Syndrome : Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl
-
- Anthony, Lowell (författare)
- Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
-
- Ervin, Claire (författare)
- RTI Hlth Solut, Res Triangle Pk, NC USA.
-
- Lapuerta, Pablo (författare)
- Lexicon Pharmaceut Inc, 8800 Technol Forest Pl, The Woodlands, TX 77385 USA.
-
visa fler...
-
- Kulke, Matthew H. (författare)
- Dana Farber Canc Inst, Boston, MA 02115 USA.
-
- Kunz, Pamela (författare)
- Stanford Canc Ctr, Stanford, CA USA.
-
- Bergsland, Emily (författare)
- UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
-
- Hörsch, Dieter (författare)
- Zent Klin Bad Berka GmbH, Klin Innerre Med Gastroenterol & Endokrinol, Bad Berka, Germany.
-
- Metz, David C. (författare)
- Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
-
- Pasieka, Janice (författare)
- Tom Baker Canc Clin, Calgary, AB, Canada.
-
- Paylakis, Nick (författare)
- Royal North Shore Hosp, St Leonards, NSW, Australia.
-
- Pavel, Marianne (författare)
- Charite, Berlin, Germany.
-
- Caplin, Martyn (författare)
- Royal Free Hosp, London, England.
-
- Öberg, Kjell, 1946- (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Ramage, John (författare)
- Hampshire Hosp NHS Trust, Basingstoke & North Hampshire Hosp, Basingstoke, Hants, England.
-
- Evans, Emily (författare)
- RTI Hlth Solut, Res Triangle Pk, NC USA.
-
- Yang, Qi Melissa (författare)
- Lexicon Pharmaceut Inc, 8800 Technol Forest Pl, The Woodlands, TX 77385 USA.
-
- Jackson, Shanna (författare)
- Lexicon Pharmaceut Inc, 8800 Technol Forest Pl, The Woodlands, TX 77385 USA.
-
- Arnold, Katie (författare)
- Lexicon Pharmaceut Inc, 8800 Technol Forest Pl, The Woodlands, TX 77385 USA.
-
- Law, Linda (författare)
- Lexicon Pharmaceut Inc, 8800 Technol Forest Pl, The Woodlands, TX 77385 USA.;BioHealthConsult, 2143 Riverside Dr, Cincinnati, OH 45202 USA.
-
- DiBenedetti, Dana B. (författare)
- RTI Hlth Solut, Res Triangle Pk, NC USA.
-
visa färre...
-
Univ Kentucky, Markey Canc Ctr, Lexington, KY USA RTI Hlth Solut, Res Triangle Pk, NC USA. (creator_code:org_t)
- Elsevier, 2017
- 2017
- Engelska.
-
Ingår i: Clinical Therapeutics. - : Elsevier. - 0149-2918 .- 1879-114X. ; 39:11, s. 2158-2168
- Relaterad länk:
-
https://uu.diva-port... (primary) (Raw object)
-
visa fler...
-
http://www.clinicalt...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Purpose: Telotristat ethyl, an oral tryptophan hydroxylase inhibitor, is intended to treat carcinoid syndrome by reducing serotonin production. Telotristat ethyl was evaluated in FELESTAR, a Phase HI study for patients who had carcinoid syndrome with at least 4 bowel movements (BMs) per day and who were receiving somatostatin analogue therapy. This interview sub study was conducted to provide insight into the patient experience in ILLESTAR and to help understand whether reductions in BM frequency (the primary end point) and other symptoms were clinically meaningful. Methods: Participating sites were asked to invite (before randomization) all eligible patients to telephone interviews scheduled at the end of the double-blind treatment period. Patients and interviewers were blinded to treatment. Findings: All 35 interviewed participants reported diarrhea and/or excessive BMs at baseline. Patients reported that these symptoms negatively affected emotional, social, physical, and occupational well-being. Prespecified criteria for treatment response (achieving >= 30% reduction in BM frequency for at least 50% of the days) were met by 8 of 26 patients taking telotristat ethyl and 1 of 9 patients taking placebo. All 8 patients taking telotristat ethyl described clinically meaningful reductions in BM frequency and were very satisfied with the ability of the study drug to control their carcinoidsyndrome symptoms. Overall, reports of being very satisfied were observed in 12 patients taking telotristat ethyl and 0 taking placebo. Implications: Patient interviews revealed that I ELESTAR patients, at baseline, were significantly affected by their high BM frequency. Patient reports of their clinical trial experience supported the significance of the primary end point and clinical responder analysis in TELESTAR, helping identify and understand clinically meaningful change produced by telotristat ethyl. (C) 2017 The Authors. Published by Elsevier HS Journals, Inc.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Samhällsfarmaci och klinisk farmaci (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Social and Clinical Pharmacy (hsv//eng)
Nyckelord
- bowel movement
- carcinoid syndrome
- diarrhea
- exit interviews
- patient interviews
- telotristat ethyl
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Anthony, Lowell
-
Ervin, Claire
-
Lapuerta, Pablo
-
Kulke, Matthew H ...
-
Kunz, Pamela
-
Bergsland, Emily
-
visa fler...
-
Hörsch, Dieter
-
Metz, David C.
-
Pasieka, Janice
-
Paylakis, Nick
-
Pavel, Marianne
-
Caplin, Martyn
-
Öberg, Kjell, 19 ...
-
Ramage, John
-
Evans, Emily
-
Yang, Qi Melissa
-
Jackson, Shanna
-
Arnold, Katie
-
Law, Linda
-
DiBenedetti, Dan ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Farmakologi och ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Samhällsfarmaci ...
- Artiklar i publikationen
-
Clinical Therape ...
- Av lärosätet
-
Uppsala universitet